1
|
Keshri AK, Rawat SS, Chaudhary A, Sharma S, Kapoor A, Mehra P, Kaur R, Mishra A, Prasad A. LL-37, the master antimicrobial peptide, its multifaceted role from combating infections to cancer immunity. Int J Antimicrob Agents 2025; 65:107398. [PMID: 39643165 DOI: 10.1016/j.ijantimicag.2024.107398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2024] [Revised: 11/16/2024] [Accepted: 11/28/2024] [Indexed: 12/09/2024]
Abstract
Antimicrobial peptides (AMPs) represent a unique group of naturally occurring molecules having diverse biological activities, including potent antimicrobial properties. Among them, LL-37 has emerged as a significant player, demonstrating its multifaceted roles during bacterial, fungal, and viral infections, as well as exhibiting intriguing implications in cancer. This review delves into the versatile functions of LL-37, elucidating its mechanisms of action against microbial pathogens and its potential to modulate immune responses. We explored the efficacy of LL-37 in disrupting bacterial membranes, inhibiting fungal growth, and interfering with viral replication, highlighting its potential as a therapeutic agent against a wide array of infectious diseases. Furthermore, we discussed the emerging role of LL-37 in cancer immunity, where its immunomodulatory effects and direct cytotoxicity towards cancer cells offer novel avenues for cancer therapy in the near future. We provided a comprehensive overview of the activities of LL-37 across various diseases and underscored the importance of further research into harnessing the therapeutic potential of this potential antimicrobial peptide along with other suitable candidates.
Collapse
Affiliation(s)
- Anand K Keshri
- School of Biosciences and Bioengineering, Indian Institute of Technology Mandi, Mandi, Himachal Pradesh, India
| | - Suraj S Rawat
- School of Biosciences and Bioengineering, Indian Institute of Technology Mandi, Mandi, Himachal Pradesh, India
| | - Anubha Chaudhary
- School of Biosciences and Bioengineering, Indian Institute of Technology Mandi, Mandi, Himachal Pradesh, India
| | - Swati Sharma
- School of Biosciences and Bioengineering, Indian Institute of Technology Mandi, Mandi, Himachal Pradesh, India
| | - Ananya Kapoor
- School of Biosciences and Bioengineering, Indian Institute of Technology Mandi, Mandi, Himachal Pradesh, India
| | - Parul Mehra
- School of Biosciences and Bioengineering, Indian Institute of Technology Mandi, Mandi, Himachal Pradesh, India
| | - Rimanpreet Kaur
- School of Biosciences and Bioengineering, Indian Institute of Technology Mandi, Mandi, Himachal Pradesh, India
| | - Amit Mishra
- Cellular and Molecular Neurobiology Unit, Indian Institute of Technology Jodhpur, Rajasthan, India
| | - Amit Prasad
- School of Biosciences and Bioengineering, Indian Institute of Technology Mandi, Mandi, Himachal Pradesh, India; Indian Knowledge System and Mental Health Application Centre, Indian Institute of Technology Mandi, Himachal Pradesh, India.
| |
Collapse
|
2
|
Chernov AN, Skliar SS, Kim AV, Tsapieva A, Pyurveev SS, Filatenkova TA, Matsko MV, Ivanov SD, Shamova OV, Suvorov AN. Glioblastoma Multiforme: Sensitivity to Antimicrobial Peptides LL-37 and PG-1, and Their Combination with Chemotherapy for Predicting the Overall Survival of Patients. Pharmaceutics 2024; 16:1234. [PMID: 39339270 PMCID: PMC11435188 DOI: 10.3390/pharmaceutics16091234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2024] [Revised: 08/25/2024] [Accepted: 09/15/2024] [Indexed: 09/30/2024] Open
Abstract
Background/Objectives: Glioblastomas (GBMs) are the most malignant and intractable of all cancers, with an unfavorable clinical prognosis for affected patients. The objective was to analyze the sensitivity of GBM cells to the antimicrobial peptides (AMPs) cathelicidin (LL-37) and protegrin-1 (PG-1), both alone and in combination with chemotherapy, to predict overall survival (OS) in the patients. Methods: The study was conducted on 27 GBM patients treated in the neurosurgical department of the Almazov Medical Research Centre (Saint Petersburg, Russia) from 2021 to 2024. The cytotoxic effects of chemotherapy, AMPs, and their combinations on brain tumor cells were assessed by an MTT assay using a 50% inhibitory concentration (IC50). Results: In GBM cells from the patients, LL-37 and PG-1 exhibited strong anticancer effects, surpassing those of chemotherapy drugs. These LL-37 and PG-1 anticancer effects were associated with a statistically significant increase in life expectancy and OS in GBM patients. These findings were confirmed by experiments on rats with C6 glioma, where the intranasal administration of LL-37 (300 μM) and PG-1 (600 μM) increased the life expectancy of the animals to 69 and 55 days, respectively, compared to 24 days in the control group (HR = 4.139, p = 0.0005; HR = 2.542, p = 0.0759). Conclusions: Additionally, the combination of LL-37 and PG-1 with chemotherapy drugs showed that a high IC50 of LL-37 with cisplatin (cutoff > 800 μM) in GBM cells was associated with increased life expectancy (19 vs. 5 months, HR = 4.708, p = 0.0101) and OS in GBM patients. These combinations could be used in future GBM treatments.
Collapse
Affiliation(s)
- Alexander N. Chernov
- World-Class Research Center “Center for Personalized Medicine”, Federal State Budgetary Institution of Science “Institute of Experimental Medicine”, 197376 Saint Petersburg, Russia; (A.T.); (T.A.F.); (O.V.S.); (A.N.S.)
- Federal State Budgetary Educational Institution of Higher Education, St. Petersburg State Pediatric Medical University of the Ministry of Health of Russia, 194100 Saint Petersburg, Russia;
| | - Sofia S. Skliar
- Children’s Neurosurgical Department No. 7, Almazov Medical Research Centre, 197341 Saint Petersburg, Russia;
| | - Alexander V. Kim
- Laboratory of Neurooncology of Polenov Neurosurgical Institute, Almazov National Medical Research Centre, 197341 Saint Petersburg, Russia;
| | - Anna Tsapieva
- World-Class Research Center “Center for Personalized Medicine”, Federal State Budgetary Institution of Science “Institute of Experimental Medicine”, 197376 Saint Petersburg, Russia; (A.T.); (T.A.F.); (O.V.S.); (A.N.S.)
| | - Sarng S. Pyurveev
- Federal State Budgetary Educational Institution of Higher Education, St. Petersburg State Pediatric Medical University of the Ministry of Health of Russia, 194100 Saint Petersburg, Russia;
| | - Tatiana A. Filatenkova
- World-Class Research Center “Center for Personalized Medicine”, Federal State Budgetary Institution of Science “Institute of Experimental Medicine”, 197376 Saint Petersburg, Russia; (A.T.); (T.A.F.); (O.V.S.); (A.N.S.)
| | - Marina V. Matsko
- Scientific Department of State Budgetary Healthcare Institution Saint-Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological) named N.P. Napalkov, 197758 Saint Petersburg, Russia;
- Department of Oncology, Medical and Social Institute, Saint-Petersburg University, 199034 Saint Petersburg, Russia
| | - Sergey D. Ivanov
- FGBU N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of the Russian Federation, 197758 Saint Petersburg, Russia;
| | - Olga V. Shamova
- World-Class Research Center “Center for Personalized Medicine”, Federal State Budgetary Institution of Science “Institute of Experimental Medicine”, 197376 Saint Petersburg, Russia; (A.T.); (T.A.F.); (O.V.S.); (A.N.S.)
- Saint Petersburg State University, 199034 Saint Petersburg, Russia
| | - Alexander N. Suvorov
- World-Class Research Center “Center for Personalized Medicine”, Federal State Budgetary Institution of Science “Institute of Experimental Medicine”, 197376 Saint Petersburg, Russia; (A.T.); (T.A.F.); (O.V.S.); (A.N.S.)
- Saint Petersburg State University, 199034 Saint Petersburg, Russia
| |
Collapse
|
3
|
Liu Y, Yu R, Wang X, Chen Y, Yin T, Gao Q, Sun L, Zheng Z. Research progress of the effective active ingredients of Astragalus mongholicus in the treatment of diabetic peripheral neuropathy. Biomed Pharmacother 2024; 173:116350. [PMID: 38430632 DOI: 10.1016/j.biopha.2024.116350] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2023] [Revised: 02/15/2024] [Accepted: 02/23/2024] [Indexed: 03/05/2024] Open
Abstract
Diabetic peripheral neuropathy (DPN) is one of the most prevalent consequences of diabetes, with a high incidence and disability rate. The DPN's pathogenesis is extremely complex and yet to be fully understood. Persistent high glucose metabolism, nerve growth factor deficiency, microvascular disease, oxidative stress, peripheral nerve cell apoptosis, immune factors, and other factors have been implicated in the pathogenesis of DPN. Astragalus mongholicus is a commonly used plant used to treat DPN in clinical settings. Its rich chemical components mainly include Astragalus polysaccharide, Astragalus saponins, Astragalus flavones, etc., which play a vital role in the treatment of DPN. This review aimed to summarize the pathogenesis of DPN and the studies on the mechanism of the effective components of Astragalus mongholicus in treating DPN. This is of great significance for the effective use of Chinese herbal medicine and the promotion of its status and influence on the world.
Collapse
Affiliation(s)
- Yulian Liu
- Department of Rehabilitation Medicine,The Affiliated Taian City Central Hospital of Qingdao University, Taian 271000, China
| | - Runyuan Yu
- Department of Rehabilitation Medicine,The Affiliated Taian City Central Hospital of Qingdao University, Taian 271000, China
| | - Xiaoyu Wang
- Department of Rehabilitation Medicine,The Affiliated Taian City Central Hospital of Qingdao University, Taian 271000, China
| | - Yuexia Chen
- Department of Skills Training Center,The Affiliated Taian City Central Hospital of Qingdao University, Taian 271000, China
| | - Tao Yin
- Department of Rehabilitation Medicine,The Affiliated Taian City Central Hospital of Qingdao University, Taian 271000, China
| | - Qiang Gao
- Department of Rehabilitation Medicine,The Affiliated Taian City Central Hospital of Qingdao University, Taian 271000, China
| | - Limin Sun
- Department of Rehabilitation Medicine,The Affiliated Taian City Central Hospital of Qingdao University, Taian 271000, China
| | - Zuncheng Zheng
- Department of Rehabilitation Medicine,The Affiliated Taian City Central Hospital of Qingdao University, Taian 271000, China.
| |
Collapse
|